Their study demonstrates that inhibiting the EZH2 methyltransferase acts in a synthetic lethal manner in ARID1A-mutated ovarian cancer cells, with ARID1A mutations correlating with the response to the EZH2 inhibitor [207]. The gene discussed is ARID1A; the disease is ovarian carcinoma.